ライフサイエンスコーパス: chronic rhinosinusitis

1 allergic rhinitis, nonallergic rhinitis, and chronic rhinosinusitis.

2 participants who underwent ESS for acute or chronic rhinosinusitis.

3 in nasal epithelial cells from patients with chronic rhinosinusitis.

4 ) and TGFbeta in pulmonary fibrosis (PF) and chronic rhinosinusitis.

5 , asthma, chronic spontaneous urticaria, and chronic rhinosinusitis.

6 stic sinuses may complicate and develop into chronic rhinosinusitis.

7 he understanding of the cognitive effects of chronic rhinosinusitis.

8 rrected for sex and the Lund-Mackay score of chronic rhinosinusitis.

9 nce to support this practice, especially for chronic rhinosinusitis.

10 review of the current literature relevant to chronic rhinosinusitis.

11 airway diseases, such as cystic fibrosis and chronic rhinosinusitis.

12 ave recently been associated with asthma and chronic rhinosinusitis.

13 llergy, in particular those of patients with chronic rhinosinusitis.

14 In patients with chronic rhinosinusitis, a novel endotyping approach pure

15 Acute exacerbations of chronic rhinosinusitis (AECRS) are commonly triggered by

16 ALI cultures of adults with chronic rhinosinusitis (AG/AA, n = 19; GG, n = 19) were

17 omorbidities of asthma, such as eosinophilic chronic rhinosinusitis, allergic rhinitis, and atopic de

18 A total of 22 patients with chronic rhinosinusitis and 22 healthy controls (2 [5%] w

19 of severe asthma complicated by eosinophilic chronic rhinosinusitis and eosinophilic otitis media, re

20 y disease (N-ERD) asthma is characterized by chronic rhinosinusitis and intolerance of aspirin and ot

21 cated in nasal polyps (NPs) of patients with chronic rhinosinusitis and might play a significant role

22 cated in nasal polyps (NPs) of patients with chronic rhinosinusitis and might play a significant role

23 All of the patients had chronic rhinosinusitis and nasal polyposis, and these re

24 ver, the exact role of microbial biofilms in chronic rhinosinusitis and orbital cellulitis were not e

25 roducing ability of the clinical isolates in chronic rhinosinusitis and orbital cellulitis, and to lo

26 enic potential of these organisms in causing chronic rhinosinusitis and orbital cellulitis.

27 sted by adult-onset asthma, nasal polyposis, chronic rhinosinusitis, and aspirin sensitivity.

28 osinophilic oesophagitis, allergic rhinitis, chronic rhinosinusitis, and asthma, are complex and infl

29 lyps, chronic obstructive pulmonary disease, chronic rhinosinusitis, and asthma.

30 c inflammation as seen in allergic rhinitis, chronic rhinosinusitis, and asthma.

31 iagnosis and treatment of allergic rhinitis, chronic rhinosinusitis, and asthma.

32 atory tract diseases including otitis media, chronic rhinosinusitis, and exacerbations of both cystic

33 ne-mediated disease characterized by asthma, chronic rhinosinusitis, and hypersensitivity to cyclooxy

34 mucosal tissue homogenates in patients with chronic rhinosinusitis, and this effect was most promine

35 These features mimic essential aspects of chronic rhinosinusitis-associated olfactory loss, and il

36 These observations establish a mechanism of chronic rhinosinusitis-associated olfactory loss, caused

37 Airway diseases such as chronic rhinosinusitis, asthma, and chronic obstructive

38 widespread prevalence of allergic, viral and chronic rhinosinusitis, but how the brain encodes and ma

39 mucin can mediate corticosteroid efficacy in chronic rhinosinusitis, but the role of MUC1 in uncontro

40 more willing to travel longer distances for chronic rhinosinusitis care, results suggest that distan

41 urgical specimens derived from patients with chronic rhinosinusitis compared to control patients.

42 .72) were at an increased risk of developing chronic rhinosinusitis compared with controls.

43 Chronic rhinosinusitis (CRS) and asthma commonly co-occu

44 Allergic rhinitis (AR), chronic rhinosinusitis (CRS) and asthma often co-exist.

45 PA) is a systemic vasculitis associated with chronic rhinosinusitis (CRS) and bronchial asthma.

46 Chronic rhinosinusitis (CRS) and bronchiectasis commonly

47 Chronic rhinosinusitis (CRS) and chronic periodontitis (

48 th chronic sinonasal inflammation, including chronic rhinosinusitis (CRS) and cystic fibrosis.

49 Asthma and chronic rhinosinusitis (CRS) are common chronic inflamma

50 chanisms and immune pathways associated with chronic rhinosinusitis (CRS) are not fully understood.

51 nd mechanisms of activation in patients with chronic rhinosinusitis (CRS) are not known.

52 of antibiotic therapy is often initiated for chronic rhinosinusitis (CRS) based on symptomatology.

53 Asthma and chronic rhinosinusitis (CRS) both impair quality of life

54 us and Moraxella species in both healthy and chronic rhinosinusitis (CRS) cohorts.

55 It is increasingly recognized that chronic rhinosinusitis (CRS) comprises a spectrum of dif

56 lines provide composite criteria to evaluate chronic rhinosinusitis (CRS) control, taking into consid

57 Chronic rhinosinusitis (CRS) defines a group of disorder

58 Chronic rhinosinusitis (CRS) epidemiology has been large

59 Chronic rhinosinusitis (CRS) has a broad range of comorb

60 Chronic rhinosinusitis (CRS) has a complex and multifact

61 Chronic rhinosinusitis (CRS) has been associated with an

62 Chronic rhinosinusitis (CRS) has been known as a disease

63 Chronic rhinosinusitis (CRS) has been linked to the gram

64 however, the association between smoking and chronic rhinosinusitis (CRS) has not been well character

65 LP protein and its function in patients with chronic rhinosinusitis (CRS) have not been fully explore

66 revalence of asthma and its association with chronic rhinosinusitis (CRS) have not been widely studie

67 Current clinical classifications of chronic rhinosinusitis (CRS) have weak prognostic utilit

68 s (EPOS) criteria to study the prevalence of chronic rhinosinusitis (CRS) in a general-population sam

69 ds (INCs) remain the first-line treatment of chronic rhinosinusitis (CRS) in both adults and children

70 host-microbial interactions in patients with chronic rhinosinusitis (CRS) in hopes of elucidating mec

71 Chronic rhinosinusitis (CRS) is a chronic inflammatory c

72 Chronic rhinosinusitis (CRS) is a chronic inflammatory d

73 Chronic rhinosinusitis (CRS) is a clinical syndrome defi

74 Chronic rhinosinusitis (CRS) is a common chronic inflamm

75 Chronic rhinosinusitis (CRS) is a common chronic inflamm

76 Chronic rhinosinusitis (CRS) is a common chronic respira

77 Chronic rhinosinusitis (CRS) is a common clinical syndro

78 Chronic rhinosinusitis (CRS) is a common condition assoc

79 Chronic rhinosinusitis (CRS) is a common condition in th

80 Chronic rhinosinusitis (CRS) is a common disease with st

81 Chronic rhinosinusitis (CRS) is a common inflammatory co

82 Chronic rhinosinusitis (CRS) is a common, heterogeneous

83 Chronic rhinosinusitis (CRS) is a complex disease consis

84 Chronic rhinosinusitis (CRS) is a complex upper airway i

85 Chronic rhinosinusitis (CRS) is a complex, heterogenous

86 Chronic rhinosinusitis (CRS) is a disease characterized

87 Chronic rhinosinusitis (CRS) is a frequent condition tha

88 Chronic rhinosinusitis (CRS) is a heterogeneous disease

89 Chronic rhinosinusitis (CRS) is a heterogeneous disease

90 Chronic rhinosinusitis (CRS) is a heterogeneous disease,

91 Chronic rhinosinusitis (CRS) is a multifactorial disease

92 Chronic rhinosinusitis (CRS) is a prevalent condition wi

93 Chronic rhinosinusitis (CRS) is a prevalent multifactori

94 Chronic rhinosinusitis (CRS) is a troublesome, chronic i

95 Chronic rhinosinusitis (CRS) is an inflammation of the n

96 Chronic rhinosinusitis (CRS) is an inflammatory disease

97 Chronic rhinosinusitis (CRS) is an inflammatory disease

98 Chronic rhinosinusitis (CRS) is an inflammatory process

99 Evidence shows that chronic rhinosinusitis (CRS) is associated with prior pr

100 Chronic rhinosinusitis (CRS) is complicated by frequent

101 Although chronic rhinosinusitis (CRS) is considered the most trea

102 Our understanding of the pathophysiology of chronic rhinosinusitis (CRS) is continuously evolving.

103 o the paranasal sinuses for diseases such as chronic rhinosinusitis (CRS) is particularly challenging

104 Data on the global prevalence of chronic rhinosinusitis (CRS) is significantly varied and

105 Chronic rhinosinusitis (CRS) is thought to result from c

106 The prevalence of chronic rhinosinusitis (CRS) measured in epidemiologic s

107 Thus, age-related cytokine profiles in chronic rhinosinusitis (CRS) need to be investigated for

108 Chronic rhinosinusitis (CRS) occurs in >10% of the adult

109 Patients with chronic rhinosinusitis (CRS) often have comorbid asthma.

110 Studies of the underlying cause or causes of chronic rhinosinusitis (CRS) over the past 20 or more ye

111 Potential effects of aging on chronic rhinosinusitis (CRS) pathophysiology have not be

112 Recently, ILC2s enrichment was noted in chronic rhinosinusitis (CRS) patients; however, the role

113 However, many patients with chronic rhinosinusitis (CRS) relay that their initiating

114 The cause of chronic rhinosinusitis (CRS) remains unclear.

115 ecretions, were collected from patients with chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP)

116 Although chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP)

117 Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP)

118 Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP)

119 y Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP),

120 tissue was obtained from subjects with AERD, chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP),

121 g hypersensitivity to NSAIDs, asthma, and/or chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP).

122 Chronic rhinosinusitis (CRS) with nasal polyps is a comm

123 patients with or without allergic rhinitis, chronic rhinosinusitis (CRS) with or without nasal polyp

124 is study aimed to explore the association of chronic rhinosinusitis (CRS) with prior chronic periodon

125 following endoscopic sinus surgery (ESS) for chronic rhinosinusitis (CRS) without nasal polyposis, th

126 Chronic rhinosinusitis (CRS) without nasal polyps (CRSsN

127 Chronic rhinosinusitis (CRS) without nasal polyps (CRSsN

128 luding eosinophilia, which is in contrast to chronic rhinosinusitis (CRS) without nasal polyps (NPs).

129 en postbronchodilator lung function, asthma, chronic rhinosinusitis (CRS), and atopy with age using a

130 in many mucosal diseases, including asthma, chronic rhinosinusitis (CRS), and eosinophilic esophagit

131 ophilia is a prominent feature of asthma and chronic rhinosinusitis (CRS), and the endothelium plays

132 F-related upper airway disease, specifically chronic rhinosinusitis (CRS), are not characterized.

133 eased in nasal polyps (NPs) of patients with chronic rhinosinusitis (CRS), as well as in bronchoalveo

134 ent of a range of nasal conditions including chronic rhinosinusitis (CRS), caused by an infection and

135 rarily classified as diffuse type 2 dominant chronic rhinosinusitis (CRS), is characterized by eosino

136 Despite the high prevalence and morbidity of chronic rhinosinusitis (CRS), little is known about the

137 nnaire items, we identified respondents with chronic rhinosinusitis (CRS), migraine headache, and fat

138 t-reported outcomes during the management of chronic rhinosinusitis (CRS), PROMs will play an essenti

139 nt algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS), respectively.

140 of the sample with subjects with asthma and chronic rhinosinusitis (CRS).

141 of the fibrinolytic system in patients with chronic rhinosinusitis (CRS).

142 sion of coagulation factors in patients with chronic rhinosinusitis (CRS).

143 important roles in inflammatory processes in chronic rhinosinusitis (CRS).

144 e thrombosis but have not been implicated in chronic rhinosinusitis (CRS).

145 e associated with an increased prevalence of chronic rhinosinusitis (CRS).

146 ronic inflammatory airway diseases including chronic rhinosinusitis (CRS).

147 systematically investigated in patients with chronic rhinosinusitis (CRS).

148 (T2) inflammation plays a pathogenic role in chronic rhinosinusitis (CRS).

149 nt algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS).

150 immunoglobulin deficiencies in patients with chronic rhinosinusitis (CRS).

151 oke (CS) plays a role in the exacerbation of chronic rhinosinusitis (CRS); however, the mechanism for

152 A definitive diagnosis of eosinophilic chronic rhinosinusitis (eCRS) requires invasive surgical

153 Eosinophilic chronic rhinosinusitis (eCRS), contemporarily classified

154 th severe asthma complicated by eosinophilic chronic rhinosinusitis (ECRS).

155 dermatitis, food allergy, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis, and as

156 lops in affected organs in asthma, rhinitis, chronic rhinosinusitis, eosinophilic esophagitis, food a

157 G, AND PARTICIPANTS: This subanalysis of the Chronic Rhinosinusitis Epidemiology Study (CRES), a pros

158 s are involved in asthma, allergic rhinitis, chronic rhinosinusitis, food allergy, and eosinophilic e

159 lated comorbidities are discussed: rhinitis, chronic rhinosinusitis, gastroesophageal reflux, obstruc

160 Invasive disease includes indolent chronic rhinosinusitis, granulomatous fungal sinusitis,

161 Chronic rhinosinusitis has a significant impact on patie

162 e relationship between allergic rhinitis and chronic rhinosinusitis has been assessed in a number of

163 ic sinus surgery and antibiotics in managing chronic rhinosinusitis has contributed to a five-times v

164 We found that patients with chronic rhinosinusitis have elevated glucose concentrati

165 of asthma (HR 0.678, 95% CI 0.636-0.722) and chronic rhinosinusitis (HR 0.799, 95% CI 0.752-0.850).

166 rhinitis (HR 1.272, 95% CI 1.214-1.333), and chronic rhinosinusitis (HR 1.744, 95% CI 1.671-1.821).

167 spite considerable research, the etiology of chronic rhinosinusitis, including the pathogenic role of

168 lly transmitted infections, cystic fibrosis, chronic rhinosinusitis, inflammatory bowel disease, and

169 Chronic rhinosinusitis is a consistent feature of the au

170 The pathogenesis of chronic rhinosinusitis is a growing area of interest, bu

171 Eosinophilic chronic rhinosinusitis is an often treatment-resistant i

172 Chronic rhinosinusitis is characterized by persistent lo

173 Chronic rhinosinusitis is common and sometimes complicat

174 es of use included acute inflammation (n=6), chronic rhinosinusitis (n=2), and allergic rhinitis (n=2

175 ory secretions in pathologic states, such as chronic rhinosinusitis or hyperglycemia, promotes tonic

176 underlying disease (asthma, nasal polyps or chronic rhinosinusitis, or both), as well as on the meth

177 substances in randomized clinical trials of chronic rhinosinusitis outcomes suggests that the use of

178 d on the 22-Item Sinonasal Outcomes Test and Chronic Rhinosinusitis Patient-Reported Outcomes Measure

179 Chronic rhinosinusitis patients with 1 CF mutation were

180 omarkers in sinonasal tissue of eosinophilic chronic rhinosinusitis patients.

181 n the identification and characterization of chronic rhinosinusitis phenotypes, endotypes, and biomar

182 dings suggest that improved understanding of chronic rhinosinusitis phenotypic and endotypic heteroge

183 pplicability of these findings to a clinical chronic rhinosinusitis population.

184 has clinical effectiveness in patients with chronic rhinosinusitis, providing significantly improved

185 Adult patients with eosinophilic chronic rhinosinusitis received 100mg mepolizumab subcut

186 tures have traditionally guided treatment in chronic rhinosinusitis, recent research has favored cate

187 Adults (aged >=18 years) with chronic rhinosinusitis remaining symptomatic following a

188 effect of nonmedicated control substances in chronic rhinosinusitis remains unclear.

189 ce of symptoms of asthma, allergic rhinitis, chronic rhinosinusitis, smoking status, and history of N

190 ns to NSAIDs was higher in participants with chronic rhinosinusitis symptoms (Odds Ratio 2.12; 95%CI

191 Among patients with nasal polyps and chronic rhinosinusitis, the prevalence was 9.69% (95% CI

192 polyp specimens from patients with AERD and chronic rhinosinusitis were analyzed by using quantitati

193 rty (240) patients with clinical features of chronic rhinosinusitis were examined; patients with firs

194 D PARTICIPANTS: A total of 505 patients with chronic rhinosinusitis were prospectively enrolled in a

195 Chronic rhinosinusitis with a type 2 inflammatory patter

196 rationales for and against the treatment of chronic rhinosinusitis with antibiotics, based on curren

197 s (AFRS) patients with samples from non-AFRS chronic rhinosinusitis with nasal polyp (CRSwNP) patient

198 Chronic rhinosinusitis with nasal polyposis (CRSwNP) in

199 Chronic rhinosinusitis with nasal polyposis (CRSwNP) is

200 Chronic rhinosinusitis with nasal polyposis (CRSwNP) is

201 Chronic rhinosinusitis with nasal polyposis (CRSwNP) is

202 The coexistence of asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) is

203 Chronic rhinosinusitis with nasal polyposis (CRSwNP) is

204 Chronic rhinosinusitis with nasal polyposis (CRSwNP) neg

205 inosinusitis (AFRS) is a severe phenotype of chronic rhinosinusitis with nasal polyposis (CRSwNP), ch

206 A role for mast cells is suggested in chronic rhinosinusitis with nasal polyposis (CRSwNP), wh

207 re asthma, but also in such comorbidities as chronic rhinosinusitis with nasal polyposis (CRSwNP).

208 desensitization (ATAD) for the management of chronic rhinosinusitis with nasal polyposis (CRSwNP).

209 ry disease (AERD) is a condition composed of chronic rhinosinusitis with nasal polyposis and asthma t

210 ab has been observed in patients with severe chronic rhinosinusitis with nasal polyposis and chronic

211 exacerbations, history of late-onset asthma, chronic rhinosinusitis with nasal polyposis, low oral co

212 fecting a subgroup of adults with asthma and chronic rhinosinusitis with nasal polyposis.

213 iomarkers in atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and eo

214 The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and ov

215 d with uncinate tissue (UT) of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and th

216 ma with an eosinophilic phenotype (SAEP) and chronic rhinosinusitis with nasal polyps (CRSwNP) are pr

217 A number of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) are re

218 Chronic rhinosinusitis with nasal polyps (CRSwNP) associ

219 Chronic rhinosinusitis with nasal polyps (CRSwNP) can be

220 The management of chronic rhinosinusitis with nasal polyps (CRSwNP) can be

221 Chronic rhinosinusitis with nasal polyps (CRSwNP) causes

222 Polyps from patients with chronic rhinosinusitis with nasal polyps (CRSwNP) contai

223 p recurrence (PR) can occur in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) follow

224 Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) genera

225 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a c

226 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a c

227 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a p

228 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a p

229 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a t

230 composition of patients with diffuse type 2 chronic rhinosinusitis with nasal polyps (CRSwNP) is alt

231 Chronic rhinosinusitis with nasal polyps (CRSwNP) is ass

232 Chronic rhinosinusitis with nasal polyps (CRSwNP) is ass

233 Chronic rhinosinusitis with nasal polyps (CRSwNP) is ass

234 Although chronic rhinosinusitis with nasal polyps (CRSwNP) is cha

235 Chronic rhinosinusitis with nasal polyps (CRSwNP) is cha

236 Chronic rhinosinusitis with nasal polyps (CRSwNP) is cha

237 Chronic rhinosinusitis with nasal polyps (CRSwNP) is cha

238 Chronic rhinosinusitis with nasal polyps (CRSwNP) is gen

239 Chronic rhinosinusitis with nasal polyps (CRSwNP) is oft

240 Chronic rhinosinusitis with nasal polyps (CRSwNP) is one

241 n of PD-1 and its ligands PD-L1 and PD-L2 in chronic rhinosinusitis with nasal polyps (CRSwNP) is poo

242 Patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) often

243 Chronic rhinosinusitis with nasal polyps (CRSwNP) sympto

244 osinusitis without nasal polyps (CRSsNP) and chronic rhinosinusitis with nasal polyps (CRSwNP) using

245 l stem/progenitor cells (BSCs) obtained from chronic rhinosinusitis with nasal polyps (CRSwNP) when d

246 nts across multiple outcomes of treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) with d

247 y disease (AERD) is characterized by asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and a

248 hinosinusitis without nasal polyps (CRSsNP), chronic rhinosinusitis with nasal polyps (CRSwNP), and a

249 matory airway diseases, including asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), and i

250 ease (AERD) is characterized by the triad of chronic rhinosinusitis with nasal polyps (CRSwNP), asthm

251 oscopy is not only used for the diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP), but a

252 is evidence of pathophysiologic diversity in chronic rhinosinusitis with nasal polyps (CRSwNP), but d

253 RD) is a mechanistically distinct subtype of chronic rhinosinusitis with nasal polyps (CRSwNP).

254 effective treatment for severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).

255 s, severity, and treatment responsiveness of chronic rhinosinusitis with nasal polyps (CRSwNP).

256 om difficult-to-treat primary diffuse type 2 chronic rhinosinusitis with nasal polyps (CRSwNP).

257 , and quality-of-life score in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

258 s of severity among patients who suffer from chronic rhinosinusitis with nasal polyps (CRSwNP).

259 air has never been assessed in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

260 lucocorticoid receptor (GR) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

261 ssed in the setting of allergic rhinitis and chronic rhinosinusitis with nasal polyps (CRSwNP); howev

262 turbinate mucosa obtained from patients with chronic rhinosinusitis with nasal polyps (n = 7) and pat

263 (181 [35%] female and 333 [65%] male), with chronic rhinosinusitis with nasal polyps (n=410) or chro

264 Chronic rhinosinusitis with nasal polyps (NP) and allerg

265 ve in treating patients with type-2 dominant chronic rhinosinusitis with nasal polyps (T2-CRSwNP).

266 ronic prurigo, chronic urticaria, asthma and chronic rhinosinusitis with nasal polyps - with a high n

267 hronic airway inflammatory diseases, such as chronic rhinosinusitis with nasal polyps and asthma, sho

268 aureus in the initiation and persistence of chronic rhinosinusitis with nasal polyps and asthma.

269 Ninety-four patients with chronic rhinosinusitis with nasal polyps and prospective

270 piratory disease compared with patients with chronic rhinosinusitis with nasal polyps and/or asthma a

271 to occur in as many as 15% of patients with chronic rhinosinusitis with nasal polyps and/or asthma.

272 Following the trend in asthma, endotypes for chronic rhinosinusitis with nasal polyps have been estab

273 ated respiratory disease is a severe form of chronic rhinosinusitis with nasal polyps in which nearly

274 Chronic rhinosinusitis with nasal polyps is associated w

275 Chronic rhinosinusitis with nasal polyps is characterize

276 Chronic rhinosinusitis with nasal polyps is frequently m

277 d safety in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps is unknown.

278 evated C3/C3a in patients with asthma and/or chronic rhinosinusitis with nasal polyps may account for

279 n atopic diseases such as atopic dermatitis, chronic rhinosinusitis with nasal polyps, and asthma.

280 wn to include chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and food aller

281 D) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and a

282 D) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an

283 severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its effica

284 ic spontaneous urticaria, atopic dermatitis, chronic rhinosinusitis with nasal polyps, food allergies

285 the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, or chronic spo

286 In patients with chronic rhinosinusitis with nasal polyps, primary human

287 ilumab for 3 months for severe asthma and/or chronic rhinosinusitis with nasal polyps.

288 placebo in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps.

289 e in the airways of patients with asthma and chronic rhinosinusitis with nasal polyps.

290 ct the host from infections in patients with chronic rhinosinusitis with nasal polyps.

291 Patients with physician-diagnosed chronic rhinosinusitis with NP of any severity ongoing a

292 grade, and quality of life in patients with chronic rhinosinusitis with NPs.

293 ongside intranasal medication in adults with chronic rhinosinusitis with or without nasal polyps.

294 f asthma (n = 71,481), CRSwNP (n = 9626) and chronic rhinosinusitis without nasal polyposis (CRSsNP,

295 a range of premorbid medical conditions for chronic rhinosinusitis without nasal polyps (CRSsNP) and

296 of IL-19, at lower extent, in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) in

297 luids (NLFs) from controls and patients with chronic rhinosinusitis without nasal polyps (CRSsNP), ch

298 is with nasal polyps (CRSwNP) and those with chronic rhinosinusitis without nasal polyps (CRSsNP; P <

299 rhinosinusitis with nasal polyps (n=410) or chronic rhinosinusitis without nasal polyps (n=104), wer

300 surgery from control subjects, patients with chronic rhinosinusitis without nasal polyps, and patient